EyePoint Inc

CEO Jay Dunker’s $2.4 M insider sale to a family trust shows how EyePoint’s leadership balances liquidity with unchanged ownership, leaving the company’s Duravyu pipeline, payer strategy, and tech initiatives as the true drivers for investors.

EyePoint CFO’s sell‑and‑rebuy of 5,000 shares reveals a portfolio‑restructuring move, not a negative signal. The strategy hints at insider confidence amid a 122% YTD stock rally.

EyePoint insider trades reveal short‑term tactics amid a growing retinal implant pipeline; see how these moves align with Phase III data, safety milestones, and future regulatory plans for EpiCure™ and gene therapy.

EyePoint Inc.’s CMO buys shares at $8.26 while selling options at no cost, signaling confidence in the company’s future drug‑device pipeline and potential upside from upcoming clinical and regulatory milestones.